A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: A Canadian perspective

Clinical Infectious Diseases

Volumn 41, Issue 1 SUPPL., 2005, Pages

  Conway, Brian ^a   Grebely, Jason ^a   Tossonian, Harout ^a   Lefebvre, Dennis ^a   De Vlaming, Stanley ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATAZANAVIR; AZITHROMYCIN; CD4 ANTIGEN; COCAINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

BACTERIAL INFECTION; CANADA; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG SELF ADMINISTRATION; GENOTYPE; HAEMOPHILUS INFLUENZAE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; JAUNDICE; LYMPHOCYTE COUNT; MENTAL DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SUBSTANCE ABUSE; TREATMENT OUTCOME; URBAN POPULATION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL INFECTIONS; CANADA; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; POVERTY AREAS; SUBSTANCE ABUSE, INTRAVENOUS; URBAN POPULATION;

EID: 20844435650     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429500     Document Type: Review

References (47)

1. Patrick DM, Strathdee SA, Archibald CP, et al. Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. Int J STD AIDS 1997; 8:437-45.
2. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997; 11:F59-65.
3. Tyndall MW, Craib KJ, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr 2001; 28:351-7.
4. Reisler R, Liou S, Servoss JC, et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials [abstract 43]. In: Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment (Buenos Aires). Stockholm: International AIDS Society, 2001.
5. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med 2000; 67:429-36.
6. McCance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict 2002; 11:271-8.
7. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36:S210-9.
8. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998; 279:943-8.
9. Fischl M, Castro J, Monroig R, et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials [abstract 528]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001:202.
10. Altice FL, Mezger J, Hodges J, Bruce D, Springer S, Friedland GH. Directly observed therapy (DOT) for HIV+ drug users (IDUs) [abstract 40]. In: Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment (Paris). Stockholm: International AIDS Society, 2003:194.
11. Lucas GM, Weidle PJ, Hader S, Moore RD. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a non-randomized comparative study. Clin Infect Dis 2004; 38:S409-13.
12. + T-cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7.
13. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-30.
14. Phair JP, Mellors JW, Detels R, Margolick JB, Munoz A. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS 2002; 16:2455-9.
15. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral therapy for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288:222-35.
16. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
17. Ena J, Pasquau F. Once-a-day highly active antiretroviral therapy: a systematic review. Clin Infect Dis 2003; 36:1186-90.
18. Staszewski S, Gallant JE, Pozniak AL, et al. Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week preliminary interim results [abstract 564b]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:259.
19. Ribera E, Rodriguez D, Soler A, et al. Efficacy and safety of nevirapine, didanosine, and lamivudine as a once-daily highly active antiretroviral therapy in adult HIV-1-infected naïve patients [abstract 7.3/1]. In: Program and abstracts of the 9th European AIDS Conference (Warsaw). Paris: European AIDS Clinical Society, 2003:313.
20. Ferrer E, Fumero E, Domingo P, et al. Nevirapine-containing regimens in HIV-infected naïve patients with CD4 ≤200 cells/μL [abstract 7.3/10]. In: Program and abstracts of the 9th European AIDS Conference (Warsaw). Paris: European AIDS Clinical Society, 2003:322.
21. Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis 2004; 38:S402-8.
22. Conway, B, Prasad, J, Grebely J, et al. Comparison of male and female intravenous drug users (IVDUs) receiving HAART within a long-term directly observed therapy program (DOT) program [abstract 242P]. In: Program and abstracts of the 13th annual Canadian Conference on HIV/AIDS Research (Montreal). Vancouver: Canadian Association for HIV Research, 2004:82.
23. US Department of Human Health and Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Rockville, MD: HIV/AIDS Treatment Information Service, 2003. Available at: http://aidsinfo.nih. gov/guidelines. Accessed 2 September 2004.
24. Fargon JJ, Piliero PJ. Drug interactions associated with HAART: focus on treatments of addiction and recreational drugs. AIDS Reader 2003; 13:433-50.
25. Raffa J, Grebely J, Mead A, Smith N, de Vlaming S, Conway B. HIV-infected intravenous drug users (IVDUs) on Nevirapine or Kaletra® based HAART require different methadone dosing strategies when changing regimens [abstract 228]. In: Program and abstracts of the 13th annual Canadian Conference on HIV/AIDS Research (Montreal). Vancouver: Canadian Association for HIV Research, 2004:64.
26. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results [abstract 570]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:271.
27. Squires KE, Thiry A, Giordano M, AI424-034 International Study Team. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through wk 24 (AI424-034) [abstract H-1076]. In: Program and abstracts of the 42nd Interscience Congress on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
28. Hsyu PH, Lillibridge JH, Maroldo L, Weiss WR, Kerr BM. Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between nelfinavir and methadone [abstract 87]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2000:91.
29. Mead A, Grebely J, Raffa J, et al. Nelfinavir (NFV)-based HAART for the treatment of intravenous drug users (IVDUs) enrolled in a directly observed therapy (DOT) program [abstract 154]. In: Program and abstracts of the 12th annual Canadian Conference on HIV/AIDS Research (Halifax). Vancouver: Canadian Association for HIV Research, 2003:44.
30. Scheidegger C, Zimmerli W. Incidence and spectrum of severe medical complications among hospitalized HIV-seronegative and HIV-seropositive narcotic drug users. AIDS 1996; 10:1407-14.
31. Scheidegger C, Zimmerli W. Infectious complications in drug addicts: 7-year review of 269 hospitalized narcotic abusers in Switzerland. Rev Infect Dis 1989; 11:486-93.
32. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin and azithromycin. Mayo Clin Proc 1999; 74:613-34.
33. Tossonian H, Raffa J, Viljoen M, et al. Short course directly observed therapy (DOT) with azithromycin for bacterial infections in HIV-infected intravenous drug users (IVDUs) [abstract 207]. In: Program and abstracts of the 13th annual Canadian Conference on HIV/AIDS Research (Montreal). Vancouver: Canadian Association for HIV Research, 2004:24.
34. Molina JM, Marcelin AG, Pavie J, et al. Didanosine (DDI) in treatment-experienced HIV-infected patients: results from a randomized double blind study (AI454-176 JAGUAR) [abstract F7/4]. In: Program and abstracts of the 9th European AIDS Conference (Warsaw). Paris: European AIDS Clinical Society, 2003:310.
35. Grebely J, Tossonian H, Raffa J, et al. Virologic efficacy of once-daily Kaletra in an intravenous drug user (IVDU) population on an antiretroviral directly observed therapy (DOT) program [abstract 255P]. In: Program and abstracts of the 13th annual Canadian Conference on HIV/AIDS Research (Montreal). Vancouver: Canadian Association for HIV Research, 2004:85.
36. van Ameijden EJ, Coutinho RA. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS 1998; 12:625-33.
37. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655-61.
38. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:S11-9.
39. Patrick DM, Tyndall MW, Cornelisse PG, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 2001; 165:889-95.
40. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
41. Blatt LM, Mutchnick MG, Tong MJ, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000; 7:196-202.
42. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
43. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
44. Grebely J, Farley J, Raffa J, et al. Hepatitis C (HCV) genotype distribution in a population of intravenous drug users (IVDUs) in the Vancouver downtown eastside [abstract 59]. In: Program and abstracts of the 2nd annual Canadian Conference on Hepatitis C (Vancouver). Toronto: Canadian Viral Hepatitis Network, 2004.
45. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-93.
46. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-23.
47. Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Reader 2003; 13:344-8.